3 results
Approved WMOCompleted
Primary Objective: The primary objective for this study is to compare the efficacy of ABP 215 with bevacizumab.Secondary Objective(s): The secondary objectives are to assess the safety and immunogenicity of ABP 215 compared with bevacizumab.
Approved WMOPending
to assess the diagnostic accuracy of CSI (at 5, 10 and 15 cm proximal to the upper border of the lower esophageal sphincter) for the presence of active disease and/or complete remission in pediatric EoE.